The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5089
Abstract: Breast cancer (BC) remains the leading cause of cancer‐related deaths worldwide. High recurrence risk Luminal BC receives adjuvant chemotherapy in addition to standard hormone therapy. Considering the heterogeneity of Luminal B BC, a more accurate… read more here.
Keywords: regrouping luminal; her2 negative; luminal her2; recurrence ... See more keywords
Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor‐positive, HER2‐negative metastatic breast cancer: A real‐world multicenter study
Sign Up to like & getrecommendations! Published in 2024 at "Cancer Medicine"
DOI: 10.1002/cam4.6762
Abstract: Chidamide is a selective histone deacetylase inhibitor approved for patients with hormone receptor (HoR)‐positive and HER2‐negative metastatic breast cancer (MBC). We aimed to investigate the efficacy, safety, and treatment patterns of chidamide and identify clinicopathological… read more here.
Keywords: cancer; her2 negative; positive her2; hormone receptor ... See more keywords
A look at current and potential treatment approaches for hormone receptor‐positive, HER2‐negative early breast cancer
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34161
Abstract: The heterogeneity of hormone receptor (HR)‐positive, HER2‐negative early breast cancers reinforces the importance of individualized, risk‐adapted treatment approaches. Numerous factors contribute to the risk for recurrence, including clinical tumor features, individual biomarkers, and genomic risk.… read more here.
Keywords: her2 negative; treatment approaches; negative early; risk ... See more keywords
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience
Sign Up to like & getrecommendations! Published in 2019 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-019-05134-x
Abstract: PurposePalbociclib is approved in 1st line for hormone receptor (HR)-positive HER2-negative advanced breast cancer (ABC). A Compassionate Access Programme previously allowed patients to receive it in 4th line. However, Palbociclib has not been specifically tested… read more here.
Keywords: positive her2; her2 negative; breast cancer;
Oral or intravenous vinorelbine plus capecitabine in heavily pretreated HER2 negative metastatic breast cancer; similar effect or quality of life?
Sign Up to like & getrecommendations! Published in 2019 at "Breast Cancer Research and Treatment"
DOI: 10.1007/s10549-019-05220-0
Abstract: I want to congratulate Torres and their colleagues [1] in which they investigated evaluated the efficacy and safety of the Vinorelbine/Capecitabine doublet (VINOCAP) in heavily pretreated HER2 negative metastatic breast cancer (MBC) patients with vinorelbine… read more here.
Keywords: vinorelbine; heavily pretreated; breast cancer; her2 negative ... See more keywords
Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain
Sign Up to like & getrecommendations! Published in 2017 at "Clinical and Translational Oncology"
DOI: 10.1007/s12094-017-1784-1
Abstract: BackgroundEverolimus with exemestane has shown promising activity in patients with hormone-receptor (HR)-positive HER2-negative endocrine-resistant advanced breast cancer. It is necessary, therefore, to characterize the safety profile of this new combination in the real-world clinical setting… read more here.
Keywords: trial; positive her2; safety; breast cancer ... See more keywords
RESILIENCE: Phase III Randomized, Double‐Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2‐Negative Breast Cancer
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Breast Cancer"
DOI: 10.1016/j.clbc.2017.05.006
Abstract: Micro‐Abstract A previous randomized phase II trial suggested that sorafenib might enhance the efficacy of capecitabine in patients with metastatic breast cancer. However, in this randomized, placebo‐controlled phase trial of 537 patients with advanced HER2‐negative… read more here.
Keywords: placebo; her2 negative; capecitabine; breast cancer ... See more keywords
The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC.
Sign Up to like & getrecommendations! Published in 2021 at "Clinical breast cancer"
DOI: 10.1016/j.clbc.2021.10.007
Abstract: Endocrine therapy (ET) for the treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive/HER2-negative) metastatic breast cancer (MBC) has changed markedly over recent years with the emergence of new ETs and the… read more here.
Keywords: patients positive; chemotherapy; negative mbc; her2 negative ... See more keywords
Combination of breast imaging parameters obtained from 18F-FDG PET and CT scan can improve the prediction of breast-conserving surgery after neoadjuvant chemotherapy in luminal/HER2-negative breast cancer.
Sign Up to like & getrecommendations! Published in 2019 at "European journal of radiology"
DOI: 10.1016/j.ejrad.2019.02.005
Abstract: INTRODUCTION The luminal/Human Epidermal growth factor Receptor 2 (HER2) negative subtype of breast cancer has low chemo-sensitivity. When neoadjuvant chemotherapy (NAC) is indicated in this subtype, before a possible breast-conserving surgery (BCS), it is more… read more here.
Keywords: fdg pet; 18f fdg; breast cancer; breast ... See more keywords
Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study
Sign Up to like & getrecommendations! Published in 2021 at "ESMO Open"
DOI: 10.1016/j.esmoop.2021.100207
Abstract: Background Quality indicators (QIs) for the management of breast cancer (BC) have been published in Europe and internationally. In Belgium, a task force was established to select measurable process indicators of systemic treatment for BC,… read more here.
Keywords: cstage iii; treatment; luminal like; like her2 ... See more keywords
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-63033-4
Abstract: The OlympiAD Phase III study (NCT02000622) established the clinical benefits of olaparib tablet monotherapy (300 mg twice daily) over chemotherapy treatment of physician’s choice (TPC) in patients with a germline BRCA1/2 mutation (gBRCAm) and human epidermal… read more here.
Keywords: subgroup; negative metastatic; asian patients; study ... See more keywords